The data illustrates the percentage of the glaucoma prescription market based on number of prescriptions in the U.S. as of 2015, by product type. As of that year, PGA-product bimatoprost had a market share of 9%.
Bimatoprost | 9 |
Travoprost | 8 |
Latanoprost | 35 |
Beta blocker | 13 |
Fixed combo | 15 |
Alpha agonist | 10 |
Carbonic anhydrase inhibitor | 8 |